Physician profile
Jonathan B Blitzer
NPI 1912967324
$2,727.33
in general payments reported to CMS, 2019-2025
27 companies · $587 in 2025
The $587 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.84 · 2020: $278 · 2021: $309 · 2022: $186 · 2023: $446 · 2024: $889 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,922.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $325.26 | 2020-2024 | Opdualag, Opdivo |
| Dendreon Pharmaceuticals LLC | $307.99 | 2024 | Provenge |
| Janssen Biotech, INC. | $281.08 | 2020-2024 | Tecvayli, Talvey |
| Astrazeneca Pharmaceuticals LP | $267.72 | 2021-2025 | Datroway, Tagrisso |
| Tempus Ai, INC | $231.18 | 2024 | Xt Cdx |
| Merck Sharp & Dohme LLC | $198.74 | 2024-2025 | Keytruda, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $198.66 | 2022-2025 | |
| Celgene Corporation | $141.12 | 2022-2024 | Reblozyl, Pomalyst |
| Genentech USA, INC. | $122.14 | 2019-2025 | Tecentriq, Polivy |
| Novartis Pharmaceuticals Corporation | $107.56 | 2021-2025 | |
| Abbvie INC. | $75.19 | 2019-2024 | |
| Glaxosmithkline, LLC. | $70.71 | 2025 | Jemperli |
| Incyte Corporation | $54.93 | 2021-2025 | Jakafi |
| Pfizer INC. | $51.44 | 2020-2023 | |
| Deciphera Pharmaceuticals INC. | $48.09 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $35.54 | 2024 | Stratafix |
| Daiichi Sankyo INC. | $32.86 | 2020 | |
| Rigel Pharmaceuticals, INC. | $28.67 | 2024 | Tavalisse, Rezlidhia |
| Array Biopharma INC | $28.41 | 2025 | Mektovi, Lorbrena, Braftovi |
| Amgen INC. | $24.01 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.85 | 2025 | |
| Puma Biotechnology, INC. | $20.31 | 2024 | |
| Azurity Pharmaceuticals, INC. | $16.99 | 2025 | Danziten |
| Eisai INC. | $12.46 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Epizyme, INC. | $11.50 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Blitzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.